. 2021 Jan 7;12:100199. doi: 10.1016/j.bbih.2021.100199

Table 3.

Findings of D3R expression in LYM of patients with SCZ.

Reference	Study	n	Sample	Methodology	Clinical features	Findings
Kwak et al., 2001	Healthy controls	31	PBLs	RT-PCR	Age of symptoms onset, Duration of illness, BPRS, ESRS, Dose of antipsychotic, Duration of no medication	Increased D3R mRNA (drug-free vs medicated and controls)
	Drug-medicated SCZ patients (»3 years)	44				No differences in D3R mRNA (drug-free vs drug-naïve)
	Drug-free SCZ patients (»3 months)	28
	Drug-naïve SCZ patients	15				After taking antipsychotics, D3R peaked at 2nd week, which later at 8th decreased
van der Weide et al., 2003	Healthy controls	8	PBLs	RT-PCR	ND	No differences in D3R mRNA
van der Weide et al., 2003	SCZ patients	8	PBLs	RT-PCR	ND	No differences in D3R mRNA
Ilani et al., 2004	Healthy controls	11	PBLs	RT-PCR	ND	Increased D3R mRNA in SCZ
Ilani et al., 2004	SCZ patients	14	PBLs	RT-PCR	ND	Increased D3R mRNA in SCZ
Vogel et al., 2004	Healthy controls	12	PBLs	RT-PCR	PANSS, BPRS, MADRS, YMRS	Reduced D3R mRNA (drug-naïve vs controls)
	Drug-naïve SCZ patients	6
	Drug-free SCZ patients (» 4 weeks)	9
	Drug-medicated SCZ patients	9
Rodrigues et al., 2005	Healthy controls	45	PBLs	Flow-cytometry	BPRS	No differences in D3R protein levels
Rodrigues et al., 2005	SCZ patients	45	PBLs	Flow-cytometry	BPRS	Significant inverse correlation (BPRS hebephrenic dimension score vs D3R)
Bonegerg et al., 2006	Healthy controls	10	Leukocyte population PBMCs	qRT-PCR	ND	Increased D3R mRNA in T cells
Bonegerg et al., 2006	SCZ patients	10	Leukocyte population PBMCs	qRT-PCR	ND	Increased D3R mRNA in T cells
Kawano et al., 2011	Healthy controls	12	PBLs	qRT-PCR	PANSS, BACS-J, Treatment dose, Duration of illness	No differences in D3R mRNA
Kawano et al., 2011	SCZ patients	11	PBLs	qRT-PCR	PANSS, BACS-J, Treatment dose, Duration of illness	D3R mRNA inversely correlated with the total PANSS score
Urhan-Kucuk et al., 2011	Healthy controls	51	PBLs	RT-PCR	ND	No differences in D3R mRNA
Urhan-Kucuk et al., 2011	SCZ patients	55	PBLs	RT-PCR	ND	Significant differences in D3R mRNA (controls vs disorganized SCZ, disorganized SCZ vs paranoid SCZ)
Ahmadian et al., 2014	Healthy controls	20	PBLs	RT-PCR	ND	D3R expressed in all groups, increased mRNA in drug-free patients vs controls and significant differences between drug-naïve patients vs controls
	Drug-naïve SCZ patients	5
	Drug-free SCZ patients (» 3 months)	15
	Drug-medicated SCZ patients (» 3 years)	22
Cui et al., 2015	Healthy controls	30	T LYM	qRT-PCR	Duration of treatment, Medication, Age of onset, PANSS	Significant differences in D3R mRNA (controls vs psychotic and SCZ/schizophreniform patients)
	Psychotic not otherwise specified patients	18
	SCZ/schizophreniform patients	14
Fernandez-Egea et al., 2016	Healthy controls	18	LYM	qRT-PCR	BMI, Smoking, BACS, CGIS	Increased D3R mRNA in clozapine-treated SCZ patients
Fernandez-Egea et al., 2016	Chronic SCZ patients	18	LYM	qRT-PCR	BMI, Smoking, BACS, CGIS	Increased D3R mRNA in clozapine-treated SCZ patients

Abbreviations: Brief Psychiatric Rating Scale (BPRS), Extrapyramidal Symptom Rating Scale (ESRS), Positive and Negative Syndrome Scale (PANSS) for Schizophrenia, Montgomery-Asberg Depression Rating Scale (MADRS), Young Mania Rating Scale (YMRS), Brief Assessment of Cognition in Schizophrenia (BACS), Body mass index (BMI), Clinical Global Impression Scale (CGIS). No Data (ND).